Singapore markets closed

ONVO Sep 2024 5.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.55000.0000 (0.00%)
As of 01:34PM EDT. Market open.
Full screen
Previous close0.5500
OpenN/A
Bid0.0000
Ask0.5000
Strike5.00
Expiry date2024-09-20
Day's range0.5500 - 0.5500
Contract rangeN/A
VolumeN/A
Open interest2
  • GlobeNewswire

    Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease

    SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces data from a poster presented at Digestive Disease Week (DDW2024) demonstrating the potential of the Company’s lead clinical-stage compound, FXR314, in combination with tofacitinib for treating inflammatory bowel disease (IBD) using 3D models and p

  • GlobeNewswire

    Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

    Renowned gastrointestinal diseases conference to held in Washington, D.C. May 18-21, 2024SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces it will be presenting data on the Company’s lead clinical-stage drug, FXR314 during DDW2024, which is being held in Washington, D.C. May 18-21, 2024. The post

  • GlobeNewswire

    Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

    SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the pricing of a public offering consisting of 6,562,500 shares of common stock (or pre-funded warrants in lieu thereof) and common warrants to purchase up to an aggregate of 6,562,500 shares of its